ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the sale, the vice president directly owned 73,424 shares in the company, valued at approximately $5,403,272.16. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Monday, September 14th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $70.79, for a total value of $35,395.00.
- On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $75.48, for a total value of $37,740.00.
ANI Pharmaceuticals Stock Performance
NASDAQ ANIP opened at $70.84 on Wednesday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $97.00. The business has a 50-day moving average price of $74.11 and a 200-day moving average price of $78.04. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 15.27, a price-to-earnings-growth ratio of 2.37 and a beta of 0.50.
Institutional Investors Weigh In On ANI Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of ANI Pharmaceuticals by 13.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 211 shares during the last quarter. Versant Capital Management Inc grew its position in ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 217 shares in the last quarter. Tidal Investments LLC purchased a new position in ANI Pharmaceuticals in the second quarter worth about $248,000. WINTON GROUP Ltd bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $4,558,000. Finally, Corient Private Wealth LP increased its stake in ANI Pharmaceuticals by 95.2% during the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock worth $1,995,000 after acquiring an additional 11,754 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective on the stock. Oppenheimer began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price on the stock. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of “Hold” and an average target price of $99.60.
View Our Latest Analysis on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.
ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
